Clin2
NCT05921253Possibly a fitRecruiting

Check a brain-heart device to reduce chemo heart risk

Breast CancerLymphoma

Part of Blood & lymphatic, Cancer, Immune system & allergy, Skin clinical trials.

This early-phase study tests a “neuromodulation” device (stimulating nerves that may affect the heart and blood vessels) to help lower cardiovascular risks after certain cancer chemotherapy. It may be most relevant if you recently had an anthracycline-based treatment and also have other heart-risk factors.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
104 people
Ages
18 years to 99 years
Study type
Interventional

Who can take part

  • Be over 18 years old
  • Have had anthracycline-based chemotherapy for breast cancer or lymphoma within the last 30 days
  • Have at least one added heart-risk factor, such as chest radiation, age over 50, type 2 diabetes, high blood pressure, current smoking, obesity, prior heart attack, known heart/valve disease, or chronic kidney disease
  • Be able to safely take part despite your heart rhythm—no atrial pacing/artificial atrial rhythm
  • Do not currently have a seizure being treated; also avoid people with a history of fainting from vasovagal episodes or with end-stage liver or kidney disease

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05223413Recruiting
Remote arm treatment to protect the heart during chemo

This trial studies whether a simple “remote conditioning” treatment on the arm can help protect the heart while you receive chemotherapy that includes anthracyclines. If you’re at higher risk for heart damage from chemo, this may reduce risk and help monitor heart function over time.

Aarhus
NCT06282796Recruiting
Early heart risk monitoring for breast cancer chemo

This study tests a method to predict and warn about heart damage from a common type of breast cancer chemotherapy. If you have HER2-positive breast cancer and will receive anthracycline drugs, this trial may help monitor your heart health.

Fuzhou, Fujian
NCT06023576Recruiting· Phase 2
Blood pressure control during breast cancer chemo

This study tests whether careful blood pressure management can help protect the heart during certain types of chemotherapy (anthracyclines) for breast cancer. Participants will use a smart blood pressure device and may also do an exercise test.

Basking Ridge, New Jersey
NCT07419711Not yet recruiting
Grape polyphenols to prevent heart damage from chemo

This trial tests whether grape polyphenols can help protect the heart in women being treated for breast cancer with certain chemotherapy drugs that can harm the heart. If you are at high risk for heart problems from chemo, this study may offer a way to reduce that risk.

NCT06491680Recruiting· Phase 4
Heart safety during breast cancer chemo

This trial checks how well the heart handles anthracycline chemotherapy in breast cancer patients. It helps doctors find early signs of heart side effects so they can keep you safe during treatment.

Cairo, Cairo Governorate
NCT06930521Recruiting
Monitoring heart health during HER2 therapy for breast cancer

This study tracks how well the heart handles HER2-targeted therapy (like Herceptin) during the first year of treatment for early-stage breast cancer. It helps keep you safe by checking heart function closely.

Toronto, Ontario

Hear when a new Breast cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.